OV101 (gaboxadol) in Angelman syndrome
OV101 is a first-in-class, oral, highly selective extrasynaptic GABAA receptor (GABAAR) agonist. It passes the blood-brain barrier and binds tightly to the unique extrasynaptic GABAA receptors on neurons throughout the brain, restoring the levels of tonic inhibition that exist when intrinsic GABAA levels are low.
OV101 is currently the only drug in clinical development for Angelman syndrome and could potentially be the first therapeutic option to make a meaningful impact in the lives of individuals with Angelman syndrome and their families. More about Angelman syndrome »
Studies of OV101 in animal models of Angelman syndrome show that the drug:
⦁ Restores tonic inhibition
⦁ Corrects motor activity
⦁ Improves gait and balance
⦁ Improves cognition and memory
Our Phase 2 clinical study STARS showed a favorable safety and tolerability profile of OV101, and a statistically significant effect versus placebo on the overall symptoms of Angelman syndrome as measured on the Clinical Global Impression scale.
Reference: Egawa K, Kitagawa K, Inoue K, et al. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome. Sci Trans Med. 2012;4(163):163ra157. doi: 10.1126/scitranslmed.3004655.
Tonic inhibition is crucial as it modulates the ability of neurons to distinguish a real signal from extraneous noise—the imbalance in tonic inhibition leads to the many of the symptoms we see in AS.
OV101 (gaboxadol) in Fragile X syndrome
OV101 is a first-in-class, oral, highly selective extrasynaptic GABAA receptor (GABAAR) agonist. It passes the blood-brain barrier and binds tightly to the unique extrasynaptic GABAA receptors on neurons throughout the brain, restoring the levels of tonic inhibition that exist when intrinsic GABAA levels are low.
OV101 is the only drug of its kind in clinical development for Fragile X syndrome. More about the unmet needs of Fragile X syndrome »
Studies of OV101 in animal models of Fragile X syndrome show that it normalizes:
⦁ Anxiety
⦁ Irritability
⦁ Repetitive behaviors
⦁ Hyperactivity
The Phase 2 study of OV101, known as the ROCKET study, has been completed and positive topline results have been released. OV101 met the study’s primary objective of safety and tolerability and produced statistically significant reductions in behavioral and functional symptoms in individuals with Fragile X syndrome. See press release >>
Reference: Cogram P, Deacon RMJ, Warner-Schmidt JL, et al. Gaboxadol normalizes behavioral abnormalities in a mouse model of Fragile X syndrome. Front Behav Neurosci 2019;13:141. DOI: 10.3389/fnbeh.2019.00141.